PRF Technologies Announces PRF-110 Demonstrated Sustained 72-Hour Analgesic Activity Comparable to Approved, Commercially Available Benchmark in Head-to-Head Preclinical Study

About this update from Prf Technologies Ltd.

Ropivacaine-only, NSAID-free formulation leverages a long-acting local anesthetic with a favorable safety profile TEL AVIV, Israel, May 26, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd. (Nasdaq: PRFX) (“PRF” or the “Company”), a clinical-stage specialty pharmaceutical company focused on reformulating established therapeutics for post-operative pain management, today announced positive results from a preclinical study in domestic pigs directly comparing its lead product candidate, PRF-110, to ZYNRELEF® (bupivacaine and meloxicam extended-release solution), an approved extended-release product used as a benchmark in the study. PRF-110 is a proprietary, oil-based, viscous, clear extended-release formulation of ropivacaine designed to be deposited directly into the surgical wound bed prior to closure. The product candidate is being developed to provide prolonged local analgesia following surgery through a single administration at the surgical site. Such product is designed to reduce the use of opiates for post-surgical pain. In the head-to-head preclinical study, PRF-110 demonstrated sustained analgesic activity comparable to ZYNRELEF across the 72-hour post-surgical evaluation period. Importantly, PRF-110 achieved this activity with a ropivacaine-only, NSAID-free formulation. Ropivacaine is a well-characterized long-acting local anesthetic that has demonstrated lower cardiac toxicity than bupivacaine in non-clinical pharmacology studies. “For physicians, the key question is whether a new non-opioid therapy can provide sustained pain relief while offering a differentiated clinical profile,” said Dr. Ehud Geller, Executive Chairman of PRF Technologies. “PRF-110 demonstrated sustained analgesic activity comparable to an approved benchmark over 72 hours in this head-to-head preclinical study. Importantly, PRF-110 achieved this activity with a ropivacaine-only, NSAID-free formulation. Given ropivacaine’s demonstrated lower cardiac toxicity than bupivacaine in non-clinical pharmacology studies, we believe PRF-110’s formulation profile may represent an important potential advantage as we evaluate the next steps in development.” Dr. Geller continued, “Post-operative pain remains a significant clinical and public health challenge, particularly as physicians and healthcare systems continue to seek effective ways to reduce reliance on opioids. Once successfully develo...

View stock analysis, news, and events for Prf Technologies Ltd.